Morgan Stanley reiterated its Equal-weight rating on Quest Diagnostics DGX. At the moment, DGX does not have a price target placed on the company's stock. On Tuesday, DGX lost 0.14% of its value to finish the day at $58.52.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
